NCPA submitted comments to the FDA to as the agency interpreted existing regulations to allow 503B outpatient facilities to sell compounds to state-licensed pharmacies. NCPA expressed concerns that FDA’s policy would likely create patient access challenges for low volume compounded medications, as well as unintended effects to patient safety. NCPA has long advocated for the ability of 503A pharmacies to be able to compound drugs within the full scope of their license and supports patient access to those compounded drugs. Learn more by reading the FDA’s draft guidance and stay tuned to qAM for more as this story develops.
NCPA
